TRRI logo

Alzex Neuropharma Stock Price

Symbol: OTCPK:TRRIMarket Cap: US$106.9kCategory: Materials

TRRI Share Price Performance

TRRI Community Fair Values

    Recent TRRI News & Updates

    No updates

    Alzex Neuropharma Inc. Key Details

    US$4.7m

    Revenue

    US$4.3m

    Cost of Revenue

    US$430.1k

    Gross Profit

    US$398.1k

    Other Expenses

    US$32.1k

    Earnings

    Last Reported Earnings
    Dec 31, 2011
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    0
    Gross Margin
    0%
    Net Profit Margin
    0%
    Debt/Equity Ratio
    0%

    Alzex Neuropharma Inc. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About TRRI

    Founded
    1971
    Employees
    n/a
    CEO
    Robert Rosner
    WebsiteView website
    www.trinresinc.com

    Alzex Neuropharma Inc., a development stage biopharmaceutical company, engages in developing therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company was formerly known as Trinity Resources Inc. and changed its name to Alzex Neuropharma Inc. in December 2022. The company was incorporated in 1971 and is headquartered in Las Vegas, Nevada.

    U.S. Market Performance

    • 7 Days: -0.6%
    • 3 Months: 11.8%
    • 1 Year: 16.8%
    • Year to Date: 7.5%
    In the last week, the market has been flat, with a notable exception in the Healthcare sector dropping 4.2%. More promisingly, the market is up 17% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading